J. Russell Teagarden, DMH

J. Russell Teagarden independently advises prescription drug payer organizations, biopharmaceutical companies, patient advocacy groups, health care policy centers, and health care research organizations on payer perspectives, research methods, and medical ethics principles and frameworks. Teagarden is a research affiliate in the Center of Biomedical Innovation at the Massachusetts Institute of Technology (MIT); a co-editor and contributor to the New York University (NYU) Literature, Arts and Medicine Database; a member of the NYU Division of Medical Ethics Working Group on Compassionate Use and Pre-Approval Access, and the Compassionate Use Advisory Committee (CompAC); a member of the Healthcare Quality Expert Committee of the United States Pharmacopeial Convention (USP); and fellow at ge2p2 Global Foundation. Until November 2014, Teagarden served as Senior Vice President of Medical & Scientific Affairs at the National Organization for Rare Disorders (NORD). Prior to NORD, he spent 19 years at Medco Health Solutions where he was chiefly involved in managing drug technology assessment, coverage policy development, coverage appeal adjudication, clinical programming development, clinical oversight, and clinical support for the company’s clients and internal departments. While there he developed ethical frameworks for pharmacy benefit allocation with colleagues from the Harvard School of Public Health. He also held leadership roles for company research initiatives, and was deeply involved in government affairs. He joined Medco after having practiced as a clinical pharmacist in critical care and drug information in the Chicago teaching hospital community.

Teagarden has a Bachelor of Science degree in Pharmacy from the University of Illinois College of Pharmacy, a Master of Arts degree in research methodology from Loyola University of Chicago, and a Doctor of Medical Humanities degree from Drew University. He completed a residency in hospital pharmacy at Northwestern University Medical Center and was a visiting scholar at the National Institutes of Health Bioethics Department. He has served as a trustee of the Institute for Safe Medication Practices and for the P&T Society. He has served on the Patient Centered Outcomes Research Institute (PCORI) Advisory Panel on Rare Disease, the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), the Oversight Body of the AMA Ethical Force program, and the National Advisory Panel of the California Health Benefits Review Program. Teagarden has held faculty appointments at several pharmacy schools and has served on deans’ advisory councils. He publishes and speaks frequently on topics including clinical research, pharmacy, health policy, ethics, education, and medical humanities.

FDavid CurryFellow